Rhythm Pharmaceuticals, Inc. RYTM Temporary Equity Accretion Of Dividends
Temporary Equity Accretion Of Dividends at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:TemporaryEquityAccretionOfDividends.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s temporary equity accretion of dividends.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s temporary equity accretion of dividends?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported temporary equity accretion of dividends of $1.1M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s temporary equity accretion of dividends changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s temporary equity accretion of dividends decreased by 16.5% year-over-year, from $1.32M to $1.1M.
- What does temporary equity accretion of dividends mean?
- This metric represents the periodic adjustment to the carrying amount of temporary equity instruments to reflect the accrual of dividends or the accretion of the instrument toward its redemption value. It captures the non-cash impact of obligations related to equity securities that are classified outside of permanent equity due to redemption features. Investors monitor this to understand the ongoing cost of capital associated with these specific equity instruments and their potential impact on earnings available to common shareholders.